Overview

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Status:
Active, not recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).

Phase:

Phase 2

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Collaborators:

Gilead Sciences
University of Miami Sylvester Comprehensive Cancer Center
Virginia Commonwealth University
Washington University School of Medicine

Treatments:

Idelalisib